Page Banner
Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Neurology

Neurology

FULL SPECTRUM OF NEUROLOGICAL DISEASE TESTING

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories. Our highly specialized neurology testing menu features more than 400 neurologist-backed assays to evaluate the simplest to most complex cases. From analyses for Alzheimer’s disease and dementia to targeted antibody detection for autoimmune neurology conditions, our robust testing library provides partners with results that move solutions through the development pipeline.

With 19 subspecialty labs that perform testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our clinical experience gives us the expertise to develop tests that deliver actionable answers.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Biopharma only testing Biopharma only testing
Biopharma only testing

Our BioPharma Diagnostics-specific neurology testing is designed to provide answers for your patients.

Full suite of neurology testing Full suite of neurology testing
Full suite of neurology testing

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Demyelinating disease Demyelinating disease
Demyelinating disease

Driven by ongoing research into the presence of antibody biomarkers in patients with immune-mediated demyelinating neuropathy, Mayo Clinic Laboratories has developed several unique, highly accurate assays that use pioneering methods to identify specific biomarkers associated with the harmful immune response. Order these tests when nerve conduction studies show prolonged distal latency or marked slowing of conduction velocities.

Epilepsy Epilepsy
Epilepsy

Proper identification of immune-mediated epilepsy is vital to directing appropriate treatment. Our autoimmune epilepsy evaluation detects for more than a dozen antibody biomarkers related to autoimmune causes.

Mitochondrial disease Mitochondrial disease
Mitochondrial disease

We offer four molecular test options that can complement radiological and histological evaluations to confirm a mitochondrial diagnosis and identify a specific mitochondrial syndrome. Rather than a series of targeted panels or single-gene analysis, we recommend sequencing the entire mitochondrial genome and/or performing a comprehensive nuclear gene panel.

Movement disorders Movement disorders
Movement disorders

Our comprehensive autoimmune movement disorders panel is continuously updated to include newly discovered antibody biomarkers and uses advanced testing approaches to detect actionable antibodies. Data-backed and developed by our autoimmune neurology experts, our evaluations include detection of several antibody biomarkers available only at Mayo Clinic Laboratories.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our distinctive approach to testing for genetic neuromuscular disorders uses phenotypic information to streamline diagnosis. Phenotype-specific panels enable targeted testing, improving diagnosis and minimizing uncertain results.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

Our hereditary peripheral neuropathy test menu includes both comprehensive and targeted NGS panels to assist in identifying genetic causes across the spectrum of peripheral neuropathies.

Sleep disorders Sleep disorders
Sleep disorders

Our testing to assess for narcolepsy evaluates for low concentrations of orexin-A/hypocretin-1 in cerebrospinal fluid. Sensitive and specific, this evaluation provides results that can guide appropriate treatment for patients.

Neurology testing overview

The rapid expansion of neurology testing has resulted in the discovery of increasing numbers of clinically relevant biomarkers. Mayo Clinic Laboratories collaborates closely with the clinical practice to develop and offer advanced testing — much of which is unavailable anywhere else — to address the most difficult questions.

Our laboratories are led by board-certified clinical neurologists and clinical chemists who have extensive experience using testing to guide patient care. These experts are available for consultations on test selection and results interpretation. Our physicians are committed to research and discovery to pave the way for the future of neurology testing.

Comprehensive disease testing

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories, including: 

  • Alzheimer's disease
  • Demyelinating disease
  • Epilepsy
  • Mitochondrial disease
  • Movement disorders
  • Neuromuscular disorders
  • Peripheral neuropathy
  • Sleep disorders
News and updates

The latest

Breakthrough Test Enhances Peripheral Neuropathy Care and Research featured image
Breakthrough Test Enhances Peripheral Neuropathy Care and Research

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.

Learn more
Phenotype-specific approach transcends traditional testing for autoimmune neurological conditions

Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.

Testicular cancer-associated paraneoplastic encephalitis

Learn more about how our movement disorders testing can help diagnose testicular cancer-associated paraneoplastic encephalitis.

Sorbitol dehydrogenase (SORD) deficiency

Learn more about how our testing protocol is useful in the diagnosis of sorbitol dehydrogenase (SORD) deficiency.

Glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder

Find out how we use glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder.

Risk of false positives with AQP4 ELISA methodology

Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.

Treatable autoimmune encephalitis diagnosed with phenotype-specific evaluation

Learn how a phenotype-specific autoimmune neurology evaluation diagnosed a treatable autoimmune encephalitis condition that was missed with a traditional paraneoplastic evaluation.

Neurofascin 155 IgG4 antibodies, a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy

Find out how our testing uses neurofascin 155 IgG4 antibodies as a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy.

MOG-IgG as a marker of acute disseminated encephalomyelitis

Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.

Autoimmune Neurology: Phenotype-Based Testing

This webinar will discuss how autoimmune neurology testing has changed with expanding antibody discovery and why a patient-first, phenotype-specific approach improves test selection and interpretation.

Multiple Sclerosis: Diagnostic Criteria Update and Kappa Free Light Chain Testing

Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.

Pediatric Autoimmune Neurologic Disorders

In this presentation, Eoin Flanagan, M.B., B.Ch., a leading specialist in neuroimmunology at Mayo Clinic, provides a clear and clinically focused overview of autoimmune conditions that affect the developing nervous system.

Breakthrough Test Enhances Peripheral Neuropathy Care and Research

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.

View More